Although a trend for better OS was noted in HER2+ patients (68%) vs. 56% in ER+/PR+ HER2− or 58% in triple negative patients, “favorable” BC subtype was not significantly predictive of better OS (p = 0.285). Here, ERBB2 is linked to breast cancer.